Ampio Clarifies ATM Program
ENGLEWOOD, Colo., Feb. 11, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today, that on February 10, 2016, it entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. ("Cantor Fitzgerald").
Michael Macaluso, Chairman and CEO, stated "During our most recent conference call, we stated that we are not currently raising money and that we have enough money to get us through 2016 and into 2017 and still complete all of our current objectives and nothing has changed since that conference call. The "at-the-market" program may be used opportunistically and as a contingency facility to strengthen our position post-Ampion trial data."
About Ampio Pharmaceuticals:
Ampio Pharmaceuticals, Inc. is a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
The securities described above are being offered by Ampio pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective on January 22, 2014. A prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, New York, New York, 10022, telephone: 212-829-7122.
Forward Looking Statements:
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "plan," "continue," "present," "could," "may," "will be," and similar expressions. These forward-looking statements include statements regarding Ampio's plans with respect to the future fund raising, Ampio's business plans, Ampion and Optina and their affects, which are subject to the risks associated with clinical trials, regulatory approvals, and changes in business conditions and similar events. These forward-looking statements also include statements regarding Ampio's strategic plans, its ability to complete the Ampion trial, the costs related thereto and the amount of securities sold under the "at-the-market" program, if any. These risks include the uncertainty of the regulatory response to the sufficiency of trial data and trial design, that regulatory approval may not be obtained or delayed, and the risks and uncertainties detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ampio-clarifies-atm-program-300218657.html
SOURCE Ampio Pharmaceuticals, Inc.